(February 6, 2019, 12:08 PM EST) -- BOSTON — The Massachusetts federal judge overseeing the Zofran multidistrict litigation on Feb. 5 denied a motion by defendant GlaxoSmithKline LLC (GSK) for preemption summary judgment, saying the question of whether there is clear evidence that the Food and Drug Administration would have rejected a birth defect warning is one for a jury (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, D. Mass., 2019 U.S. Dist. LEXIS 18327)....